Provided by Tiger Trade Technology Pte. Ltd.

Annovis Bio, Inc.

1.75
-0.0700-3.85%
Pre-market: 1.800.0500+2.86%04:00 EDT
Volume:670.72K
Turnover:1.18M
Market Cap:74.45M
PE:-0.98
High:1.83
Open:1.83
Low:1.74
Close:1.82
52wk High:5.50
52wk Low:1.54
Shares:42.54M
Float Shares:35.32M
Volume Ratio:1.11
T/O Rate:1.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7895
EPS(LYR):-1.4040
ROE:-703.68%
ROA:-142.36%
PB:-17.50
PE(LYR):-1.25

Loading ...

Company Profile

Company Name:
Annovis Bio, Inc.
Exchange:
NYSE
Establishment Date:
2008
Employees:
- -
Office Location:
101 Lindenwood Drive,Suite 225,Malvern,Pennsylvania,United States
Zip Code:
19355
Fax:
- -
Introduction:
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Directors

Name
Position
Maria Maccecchini
Founder,President,Chief Executive Officer and Director
Michael Hoffman
Chairman of the Board and Director
Claudine Bruck
Independent Director
Mark White
Independent Director
Reid McCarthy
Independent Director

Shareholders

Name
Position
Maria Maccecchini
Founder,President,Chief Executive Officer and Director
Cheng Fang
Senior Vice President, Research and Development
Eve Damiano
Senior Vice President, Regulatory
Mark Guerin
Chief Financial Officer
Mike Christie
Vice President, Process Chemistry
Sarah MacCallum
Director of Clinical Operations